Kyverna Therapeutics任命Marc Grasso为首席财务官

2025-06-30 21:32

Kyverna Therapeutics (NASDAQ:KYTX) announced on Monday the appointment of Marc Grasso as its chief financial officer (CFO), effective today.
Most recently, Grasso served as CFO of Alector, a clinical-stage biotechnology company focused on neurodegenerative diseases, where he oversaw Financial Planning and Analysis, Investor Relations, Accounting, Information Technology and Facilities. Prior to Alector, Grasso held the position of CFO and chief business officer of Kura Oncology.
In connection with the appointment of Grasso as CFO, on June 30, 2025, Kyverna will grant Grasso an option to purchase 450,000 shares of its common stock.
KYTX +3.04% premarket to $3.38.
Source: Press Release

More on Kyverna Therapeutics